Related Experiment Video
Updated: Aug 15, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
A small sample confidence interval approach to assess individual bioequivalence
T Hyslop1, F Hsuan, D J Holder
1Biostatistics Section, Division of Clinical Pharmacology, Department of Medicine, Thomas Jefferson University, 132 S. 10th Street, 1170 Main Building, Philadelphia, PA 19107-5244, USA. terry.hyslop@mail.tju.edu
Abstract:
The concept of interchangeable pharmaceutical products has been examined in great detail in the literature. Anderson and Hauck proposed a statistical random coefficient model to study 'switchability', and coined the phrase 'individual bioequivalence' which they defined with a probability-based inequality. Since that paper there has been considerable work and discussion. The Food and Drug Administration has recommended the introduction of individual bioequivalence (IBE) and population bioequivalence (PBE) methods in a draft guidance document. The proposal in the draft guidance includes criteria for IBE and PBE and recommends the use of non-parametric bootstrap 95 per cent upper confidence intervals for the conclusion of either IBE or PBE. However, this method requires intensive computations. We have developed an alternative confidence interval procedure to assess IBE by the FDA recommended criteria. This method utilizes Howe's approximation I to a Cornish-Fisher expansion. Our proposed method is applicable to balanced or unbalanced data in a broad class of extended cross-over designs, and can be easily programmed using readily available software.
More Related Videos
Related Concept Videos
Bioequivalence: Overview
Bioequivalence Experimental Study Designs: Completely Randomized and Randomized Block Designs
Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs
Bioequivalence studies: Biowaivers
Bioequivalence Data: Statistical Interpretation
Bioequivalence of Drugs: Drugs with Multiple Indications

